Zoetis Inc (ZTS)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NYSE
Market Cap: $34.29B
Last updated: Nov 17, 2026 at 4:59 PM ET
Zoetis Inc (ZTS) Statistics
Zoetis (ZTS) has a market cap of $34.29B and an enterprise value of $42.01B. Its trailing P/E of 12.6x is below its 10-year median of 31.9x. Its share count is down 7.07% from a year earlier.
Total Valuation
Enterprise value is 22.50% above the market cap, as debt exceeds cash.
| Market Cap | $34.29B |
|---|---|
| Enterprise Value | $42.01B |
| Latest price (Nov 17, 2026) | $83.47 |
Key Dates
The next earnings report is expected on Feb 10, 2027, covering the quarter ending Dec 31, 2026. The last ex-dividend date was Oct 30, 2026.
| Next Earnings Date | Feb 10, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Last Ex-Dividend Date | Oct 30, 2026 |
| Next Payment Date | Dec 1, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 3.6x and 10.4x. Its year-end P/E ranged from 19.6x to 51.9x from 2016 to 2025.
| P/E Ratio | 12.6x |
|---|---|
| Forward P/E | 13.0x |
| P/S Ratio | 3.6x |
| Forward P/S | 3.7x |
| P/B Ratio | 10.4x |
| P/FCF Ratio | 15.1x |
| P/OCF Ratio | 12.4x |
| PEG Ratio | 1.5 |
Enterprise Valuation
Counting debt and cash, the company is valued at 11.0x EBITDA and 18.5x free cash flow.
| EV / Earnings | 16.9x |
|---|---|
| EV / Sales | 4.4x |
| EV / EBITDA | 11.0x |
| EV / EBIT | 12.5x |
| EV / FCF | 18.5x |
Price Statistics
The stock is down 29.83% over 52 weeks and trades 9.40% above its 50-day average.
| Beta (1Y) | 0.60 |
|---|---|
| 52-Week Change | -29.83% |
| 1-Month Change | +5.58% |
| 3-Month Change | +9.59% |
| 6-Month Change | +6.51% |
| 5-Year Change | -63.13% |
| 10-Year Change | +66.78% |
| Total Return (1Y) | -28.05% |
| Total Return (3Y CAGR) | -20.82% |
| Total Return (5Y CAGR) | -17.13% |
| Return vs SPY (1Y) | -39.80% |
| Max Drawdown (1Y) | -47.05% |
| Max Drawdown (3Y) | -64.40% |
| Sharpe Ratio (1Y) | -0.84 |
| Correlation with SPY (1Y) | 0.21 |
| 50-Day Average | $76.30 |
| 200-Day Average | $90.29 |
| 52-Week Range | $68.31 to $130.12 |
| RSI (14 Days) | 57.8 |
| Average Volume (20 Days) | 4.56M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 2.35x current liabilities, and total debt is 2.74x shareholder equity.
| Current Ratio | 2.35x |
|---|---|
| Quick Ratio | 1.40x |
| Debt / Equity | 2.74x |
| Debt / EBITDA | 2.36x |
| Debt / FCF | 3.97x |
| Interest Coverage | 13.87x |
Returns and Efficiency
Return on invested capital is 21.69% over the last 12 months, against a 5-year average of 21.37%.
| Return on Equity (ROE) | 75.26% |
|---|---|
| Return on Assets (ROA) | 16.48% |
| Return on Invested Capital (ROIC) | 21.69% |
| Return on Capital Employed (ROCE) | 27.05% |
| ROE (5Y Average) | 54.02% |
| ROA (5Y Average) | 15.99% |
| ROIC (5Y Average) | 21.37% |
| Asset Turnover | 0.63x |
| Inventory Turnover | 1.07x |
| Receivables Turnover | 5.83x |
| Cash Conversion Cycle | 347 days |
Taxes
Income tax took 20.17% of pretax income over the last 12 months.
| Income Tax (TTM) | $628.00M |
|---|---|
| Effective Tax Rate | 20.17% |
Scores
ZTS has an Altman Z-Score of 4.82, in the safe zone above 2.99, and a Piotroski F-Score of 6 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 4.82 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 6 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $9.51B over the last 12 months is up 1.03% from the 12 months before.
| Revenue | $9.51B |
|---|---|
| Revenue Growth (YoY) | +1.03% |
| Gross Profit | $6.78B |
| Operating Income | $3.39B |
| Pretax Income | $3.11B |
| Net Income | $2.49B |
| EBITDA | $3.83B |
| EBIT | $3.36B |
| Reported EPS (TTM) | $6.63 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 21.87% of the $15.09B in total assets.
| Cash and Equivalents | $1.33B |
|---|---|
| Total Debt | $9.05B |
| Net Debt | $7.72B |
| Net Debt Per Share | $18.75 |
| Working Capital | $3.61B |
| Shareholder Equity | $3.30B |
| Book Value Per Share | $8.02 |
| Tangible Book Value | -$435.00M |
| Total Assets | $15.09B |
| Total Liabilities | $11.79B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $495.00M of capital spending, operating cash flow left $2.28B of free cash flow.
| Operating Cash Flow | $2.77B |
|---|---|
| Capital Expenditures | $495.00M |
| Free Cash Flow | $2.28B |
| FCF Per Share | $5.51 |
| Depreciation and Amortization | $478.00M |
| Dividends Paid | $886.00M |
| Share Repurchases | $3.75B |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 35.70%, against a 5-year average of 36.09%.
| Gross Margin | 71.35% |
|---|---|
| Operating Margin | 35.70% |
| Pretax Margin | 32.75% |
| Net Margin | 26.15% |
| EBITDA Margin | 40.32% |
| EBIT Margin | 35.30% |
| FCF Margin | 23.96% |
| Gross Margin (5Y Average) | 70.50% |
| Operating Margin (5Y Average) | 36.09% |
| Net Margin (5Y Average) | 26.97% |
Growth
Revenue grew 5.42% a year over 3 years, and EPS 9.57% a year.
| Revenue Growth (3Y CAGR) | +5.42% |
|---|---|
| Revenue Growth (5Y CAGR) | +7.24% |
| EPS Growth (3Y CAGR) | +9.57% |
| EPS Growth (5Y CAGR) | +10.77% |
| FCF Growth (3Y CAGR) | +19.85% |
| FCF Growth (5Y CAGR) | +6.41% |
| Operating Income Growth (3Y CAGR) | +6.73% |
| Book Value Per Share Growth (2Y CAGR) | -15.33% |
Dividends and Yields
ZTS pays out 31.47% of earnings as dividends.
| Dividend Per Share (Annual) | $2.12 |
|---|---|
| Dividend Yield | 2.54% |
| Payment Schedule | Quarterly |
| Dividend Growth (3Y CAGR) | +15.44% |
| Dividend Growth (5Y CAGR) | +20.11% |
| Payout Ratio | 31.47% |
| FCF Payout Ratio | 38.89% |
| Earnings Yield | 7.94% |
| FCF Yield | 6.63% |
| Buyback Yield | 10.91% |
| Shareholder Yield | 13.49% |
Peer Position
Against 10 similar companies, ZTS has the 9th highest P/E and the 2nd highest ROIC.
P/E RatioPeer median 21.7x
P/S RatioPeer median 2.7x
ROICPeer median 8.65%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +8.88%
Dividend YieldPeer median 0.00%
| P/E Ratio | 12.6x vs 21.7x median |
|---|---|
| P/S Ratio | 3.6x vs 2.7x median |
| ROIC | 21.69% vs 8.65% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +1.03% vs +8.88% median |
| Dividend Yield | 2.54% vs 0.00% median |
Analyst Forecast
Consensus estimates put revenue growth at -0.68% and EPS growth at -0.33% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -0.68% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | -0.33% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About ZTS
What is ZTS's market cap?
Zoetis has a market cap of $34.29B. Its enterprise value, which adds debt and subtracts cash, is $42.01B.
What is ZTS's P/E ratio?
Zoetis has a trailing P/E ratio of 12.6x and a forward P/E of 13.0x.
How many shares of ZTS are outstanding?
Zoetis has 411.60M shares outstanding. The count is down 7.07% from a year earlier.
Does ZTS pay a dividend?
Yes. Zoetis pays $2.12 a share a year, a dividend yield of 2.54%.
How much debt does ZTS have?
Zoetis has $9.05B of total debt and $1.33B of cash and equivalents, a net debt position of $7.72B.
ZTS pages: Overview, Dividends, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts